Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb;49(2):177-180.
doi: 10.1111/jop.12982. Epub 2019 Dec 23.

The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation

Paolo G Arduino  1 , Roberto Broccoletti  1 , Mario Carbone  1 , Davide Conrotto  1 , Veronica Sciannameo  2 , Alessio Gambino  3 , Marco Cabras  1 , Marco Carrozzo  4 , Simone Baldovino  5
Affiliations
Free article

The prompt use of rituximab could decrease adverse effects in patient with pemphigus vulgaris: A preliminary evaluation

Paolo G Arduino et al. J Oral Pathol Med. 2020 Feb.
Free article

Abstract

Background: The systemic use of corticosteroid is the treatment of choice for patients with pemphigus vulgaris (PV), but adverse effects are frequent. To date, the use of rituximab (RTX) for PV patients is usually indicated when they failed first-line immunosuppressive therapies. The early use of RTX could theoretically lessen adverse effects.

Methods: We performed a single-center study on patients with predominantly oral PV, treated with systemic corticosteroid and the prompt use of 1000 mg of intravenous RTX two weeks apart. We evaluated the clinical response and the reported adverse effect during a period of 24 months, comparing those with a previously published series.

Results: The study group comprised 11 patients, while the control group comprised 98 patients. The average time to achieve complete clinical remission was 3.2 ± 2.72 months. Study group took steroids for a mean time of 11.09 ± 2.02 months, and they are all actually disease-free with no medication. Only three patients (27.3%) developed plain side effects. The effect of the length of the corticosteroid therapy on the side effects (also adjusted by sex, age, and clinical oral involvement) was statistically different in the two groups: the prompt use of RTX reduced of 94% the chance to have adverse effects (P = .001).

Conclusions: This is the first report of the use of RTX as first line of therapy for PV patients with predominantly oral involvement. With the proposed regimen, the adverse effects have been minimized compared with classic systemic corticosteroid-centered therapy. Multi-center randomized controlled trail is however necessary.

Keywords: oral mucosa; pemphigus; rituximab.

PubMed Disclaimer

References

REFERENCES

    1. Arduino PG, Broccoletti R, Carbone M, et al. Long-term evaluation of pemphigus vulgaris: A retrospective consideration of 98 patients treated in an oral medicine unit in north-west Italy. J Oral Pathol Med. 2019;48:406-412.
    1. Ojaimi S, O'Connor K, Lin MW, Schifter M, Fulcher DA. Treatment outcomes in a cohort of patients with mucosal-predominant pemphigus vulgaris. Intern Med J. 2015;45:284-292.
    1. McMillan R, Taylor J, Shephard M, et al. World Workshop on Oral Medicine VI: a systematic review of the treatment of mucocutaneous pemphigus vulgaris. Oral Surg Oral Med Oral Pathol Oral Radiol. 2015;120:132-142.
    1. Cirillo N, Cozzani E, Carrozzo M, Grando SA. Urban legends: pemphigus vulgaris. Oral Dis. 2012;18:442-558.
    1. Joly P, Maho-Vaillant M, Prost-Squarcioni C, et al. First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomized trial. Lancet. 2017;389:20131-22040.